Top

Breast Cancer

Published in:

01-10-2001

E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations ofE1A gene therapy

Authors: Naoto T. Ueno, Dihua Yu, Mien-Chie Hung

Published in: Breast Cancer | Issue 4/2001

Title: E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations ofE1A gene therapy
Authors: Naoto T. Ueno
Dihua Yu
Mien-Chie Hung
Publication date: 01-10-2001
Publisher: Springer-Verlag
Published in: Breast Cancer / Issue 4/2001
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/BF02967526

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 4/2001

Aromatase and aromatase inhibitors

Treatment selection in ductal carcinomain situ

Third-generation aromatase inhibitors in the treatment of advanced breast cancer

The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer

Resistant mechanisms of anthracyclines — pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues

Adjuvant therapy for breast cancer — results from the USA consensus conference

Keynote webinar | Spotlight on antibody–drug conjugates in cancer